Samalizumab

• CAT Number: I042197
• CAS Number: 1073059-33-2
• Purity: ≥95%

Samalizumab（Cat No.:I042197）is a monoclonal antibody that targets the CD200 receptor, which is expressed on immune cells like T-cells and myeloid cells. CD200 plays a role in suppressing immune responses, particularly in the tumor microenvironment, allowing cancers to evade detection. By inhibiting CD200, samalizumab aims to reverse this immune suppression, potentially enhancing the body’s ability to recognize and destroy cancer cells. It is being studied in clinical trials for various cancers, including solid tumors and hematologic malignancies, to assess its safety, efficacy, and its potential in combination with other immunotherapies.